Profile data is unavailable for this security.
About the company
Deva Holding AS is a Turkey-based pharmaceutical company that is primarily engaged in the production and marketing of finished pharmaceutical products, pharmaceutical ingredients and veterinary products, as well as animal health products, among others. The Company has four production facilities in Turkey. Its production facilities include the Tokapi, Cerezkoy I, Cerezkoy II and Kartepe production plants. The Company’s product portfolio comprises 73 drugs, which are available on the market in 177 various forms. It offers products, such as Azitro, Alemax, Cefax, Inhibace, Imatis, Hydrea, Kardozin, Kristapen, Magcar, Magnesie Calcinee, Nostil, Oceral, Remidon, Prolixin and Quet, among others. The Company has two subsidiaries, namely Vetaa Veteriner ve Tarim Ilaclari A.S. and Deva Holding NZ Ltd.
- Revenue in TRY (TTM)17.35bn
- Net income in TRY336.72m
- Incorporated1958
- Employees3.07k
- LocationDeva Holding ASKucukcekmeceISTANBUL 34303TurkeyTUR
- Phone+90 2 126929292
- Fax+90 2 126970208
- Websitehttps://www.deva.com.tr
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Natac Natural Ingredients SA | 1.69bn | -304.17m | 15.66bn | 184.00 | -- | 7.84 | 281.66 | 9.27 | -0.0136 | -0.0136 | 0.0755 | 0.0887 | 0.2389 | 0.0504 | 4.21 | 198,840.70 | -4.30 | 1.15 | -6.32 | 1.42 | 97.29 | -- | -18.00 | 6.49 | 0.2161 | -0.2629 | 0.6672 | -- | 35.01 | 91.00 | -93.80 | 3.85 | 563.61 | -- |
| RPG Life Sciences Ltd | 3.25bn | 977.30m | 15.73bn | 1.33k | 16.09 | -- | 14.57 | 4.84 | 122.51 | 122.51 | 407.37 | -- | -- | -- | -- | 5,061,758.00 | -- | 21.05 | -- | 27.78 | 64.34 | 63.28 | 30.07 | 16.68 | -- | 174.47 | -- | 24.92 | 12.26 | 11.71 | 109.03 | 44.58 | 27.39 | 37.97 |
| Hangzhou Tianmushan Phrmtcl ntrprs C Ltd | 1.59bn | 209.76m | 15.73bn | 362.00 | 75.00 | 37.34 | -- | 9.89 | 0.2723 | 0.2723 | 2.07 | 0.5468 | 0.632 | 2.97 | 2.32 | 694,905.80 | 8.32 | -8.84 | 27.42 | -25.80 | 47.93 | 32.17 | 13.17 | -21.83 | 0.655 | 9.23 | 0.648 | -- | 78.44 | -6.06 | 139.83 | -21.36 | -26.32 | -- |
| Zhejiang East Asia Pharmaceutical Co Ltd | 5.26bn | -1.38bn | 15.77bn | 1.75k | -- | 1.37 | -- | 3.00 | -1.97 | -1.97 | 7.34 | 15.80 | 0.2409 | 0.8634 | 5.60 | 475,447.80 | -6.33 | 2.47 | -8.09 | 3.12 | 25.78 | 24.66 | -26.25 | 5.78 | 0.7513 | -411.46 | 0.3533 | 42.92 | -11.66 | 3.93 | -183.02 | -- | 29.64 | -- |
| Niox Group PLC | 2.73bn | 290.66m | 15.87bn | 84.00 | 55.94 | 4.15 | 29.39 | 5.81 | 0.0114 | 0.0122 | 0.1096 | 0.1542 | 0.5804 | 3.28 | 8.85 | 547,619.10 | 6.18 | 0.4655 | 6.66 | 0.5113 | 71.09 | 70.62 | 10.65 | 1.55 | 3.07 | -- | 0.0183 | 788.00 | 13.59 | 3.85 | -64.21 | -- | -37.28 | -- |
| Duopharma Biotech Bhd | 10.10bn | 935.92m | 15.96bn | 1.96k | 17.05 | 1.91 | 11.04 | 1.58 | 0.0868 | 0.0868 | 0.9363 | 0.7736 | 0.6425 | 2.17 | 3.96 | 460,233.50 | 5.96 | 5.22 | 7.21 | 6.30 | 38.04 | 39.04 | 9.27 | 9.04 | 1.62 | 6.65 | 0.3975 | 44.97 | 15.46 | 7.14 | 19.00 | 2.54 | -11.06 | -2.33 |
| Deva Holding AS | 17.35bn | 336.72m | 15.98bn | 3.07k | 48.25 | 0.6034 | 9.87 | 0.9214 | 1.66 | 1.66 | 87.44 | 132.42 | 0.5386 | 2.18 | 6.19 | 5,662,927.00 | 1.05 | 9.90 | 1.40 | 14.23 | 34.50 | 40.87 | 1.94 | 17.06 | 1.06 | 0.4296 | 0.1627 | 1.70 | -5.50 | 62.27 | -98.58 | -24.66 | 70.87 | -- |
| Enseval Putera Megatrading Tbk PT | 83.64bn | 1.97bn | 16.11bn | 5.08k | 8.18 | 0.8107 | 6.53 | 0.1926 | 279.85 | 279.85 | 11,888.59 | 2,824.64 | 2.74 | 7.42 | 6.71 | 6,386,735,000.00 | 6.44 | 7.53 | 9.91 | 10.81 | 10.07 | 10.47 | 2.35 | 2.80 | 1.46 | 38.64 | 0.0038 | 67.96 | 8.59 | 6.85 | 7.74 | 5.02 | -7.51 | 14.74 |
| Fuji Pharma Co Ltd | 15.56bn | 665.32m | 16.16bn | 1.76k | 23.84 | 1.16 | 9.01 | 1.04 | 95.46 | 95.46 | 2,233.29 | 1,959.48 | 0.5765 | 1.49 | 2.83 | 31,007,950.00 | 2.46 | 4.51 | 3.93 | 6.76 | 40.82 | 40.57 | 4.27 | 8.51 | 0.876 | 17.58 | 0.3885 | 25.98 | 12.01 | 8.87 | -51.19 | 7.55 | 8.07 | 7.94 |
| Orchid Pharma Ltd | 3.91bn | 91.01m | 16.25bn | 737.00 | 178.60 | -- | 63.77 | 4.15 | 3.72 | 3.72 | 160.07 | -- | -- | -- | -- | 11,006,770.00 | -- | 1.40 | -- | 1.72 | 36.82 | 35.89 | 2.14 | 2.75 | -- | 0.4822 | -- | -- | 12.48 | 13.76 | 8.13 | -- | 104.06 | -- |
Data as of Feb 18 2026. Currency figures normalised to Deva Holding AS's reporting currency: Turkish Lira TRY
0.37%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 646.90k | 0.32% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 79.23k | 0.04% |
| DFA Australia Ltd.as of 31 Dec 2025 | 9.95k | 0.01% |
| Pennsylvania State Employees' Retirement Systemas of 31 Dec 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2024 - 31 Dec 2025Source: FactSet Research Systems Inc.
